BioStem Technologies to Report First Quarter 2026 Results on May 14
BioStem Technologies will release Q1 2026 financial results on May 14, 2026, followed by a conference call and webcast at 4:30 PM ET, offering investors insight into the company's performance and growth trajectory in regenerative medicine.
BioStem Technologies, Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allograft products, announced it will release its first quarter 2026 financial results on Thursday, May 14, 2026, after the market close. The company will host a conference call and webcast at 4:30 PM ET the same day to discuss the results and provide a business update.
The webcast will feature an overview of the quarter from BioStem Technologies management. Investors and interested parties can register for the event by clicking here. The conference call can be accessed via toll-free number (800) 715-9871 in North America or internationally at +1 (646) 307-1963, using conference ID 9695874. A replay will be available on the company's website following the call.
BioStem Technologies is a publicly traded biomedical innovator focused on developing, manufacturing, and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages proprietary processing technologies, including BioRetain®, CryoTek®, and SteriTek®, designed to preserve the natural properties of these tissues for clinical use. Its allografts are utilized by clinicians across a wide range of specialties, and the company maintains a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint.
The company’s quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (AATB) and are established in compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). BioStem’s portfolio includes quality brands such as Neox®, Clarix®, VENDAJE®, and American Amnion™ product lines.
This announcement comes as BioStem continues to advance innovation in regenerative medicine. The upcoming financial results will provide investors with key insights into the company's performance and strategic direction. For the latest news and updates relating to $BSEM, visit the company’s newsroom at https://tinyurl.com/bsemnewsroom.